Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2017 | Arsanis | Series D | 0 |
3/2018 | IDEAYA Biosciences | Series B | 0 |
10/2019 | Molecular Assemblies | Series A | 0 |
1/2019 | Immusoft | Series B | 0 |
1/2020 | TwinStrand Biosciences | Series A | 16M |
10/2022 | Odyssey Therapeutics | Series B | 0 |
3/2022 | Umaro Foods | Seed Round | 0 |
5/2022 | Pleno | Seed Round | 0 |
3/2022 | Eclipse Bioinnovations | Series A | 14M |
4/2022 | Pheast Therapeutics | Series A | 0 |
10/2021 | Immunai | Series B | 215M |
5/2021 | Inari | Series D | 0 |
10/2021 | Crop Enhancement | Convertible Note | - |
8/2021 | Humacyte | PIPE | 175M |
9/2021 | LEXEO Therapeutics | Series B | 0 |
12/2017 | Aura Biosciences | Series C | 0 |
6/2021 | TRex Bio | Series A | 59M |
1/2020 | Novome Biotechnologies | Series A | 0 |
5/2021 | Invaio Sciences | Series C | 88.9M |
3/2019 | Cardea Bio | Series A | 7.8M |
9/2018 | BlueLight Therapeutics | Series C | 20M |
9/2021 | Kytopen | Series A | 0 |
9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
4/2023 | Function Oncology | Series A | 28M |
5/2018 | Celsius Therapeutics | Series A | 65M |
9/2020 | Korro Bio | Series A | 0 |
8/2021 | Immunitas Therapeutics | Series B | 0 |
11/2021 | Parthenon Therapeutics | Series A | 0 |
12/2018 | Kallyope | Series B | 21M |
6/2019 | Encoded Therapeutics | Series C | 104M |
7/2022 | Ozette Technologies | Series A | 0 |
12/2019 | Aspen Neuroscience | Seed Round | 0 |
8/2018 | Inari | Series B | 40M |
7/2022 | Cartography Biosciences | Series A | 0 |
11/2022 | Haystack Oncology | Series A | 56M |
12/2020 | Faze Medicines | Series A | 81M |
2/2022 | Harpe Bio | Convertible Note | 3.2M |
7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
2/2022 | Harpe Bio | Venture Round | 3M |
1/2021 | LEXEO Therapeutics | Series A | 0 |
3/2019 | Gencove | Seed Round | 3M |
9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
6/2021 | Bright Peak Therapeutics | Series B | 107M |
7/2021 | Deep Genomics | Series C | 0 |
7/2017 | Rodeo Therapeutics | Series A | 5.9M |
8/2021 | Thryv Therapeutics | Series A | 0 |
2/2023 | Paratus Sciences | Series A | 0 |
3/2017 | Boragen | Series A | 10M |
12/2022 | SonoThera | Series A | 0 |
3/2017 | EGenesis | Series A | 0 |
6/2021 | ImmuneID | Series A | 0 |
3/2019 | Karuna Therapeutics | Series B | 0 |
6/2020 | Autobahn Therapeutics | Series B | 76M |
4/2023 | Orbital Therapeutics | Series A | 0 |
11/2021 | Fountain Therapeutics | Series A | 0 |
7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
3/2020 | Kallyope | Series C | 112M |
5/2018 | Insitro | Series A | 100M |
5/2022 | Remix Therapeutics | Series B | 0 |
9/2017 | LifeMine Therapeutics | Series A | 0 |
11/2018 | Caraway Therapeutics | Series A | 23M |
11/2021 | Nitrase Therapeutics | Series A | 0 |
10/2017 | Visterra | Series C | 0 |
6/2018 | StrideBio | Series A | 15.7M |
11/2021 | GeneCentric Therapeutics | Series B | 0 |
5/2023 | Ten63 Therapeutics | Series A | 0 |
7/2021 | IgGenix | Series A | 0 |
6/2018 | Precision BioSciences | Series B | 0 |
7/2017 | Evelo Biosciences | Series B | 50M |
7/2019 | GNS Healthcare | Series D | 23M |
9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
12/2019 | Jasper Therapeutics | Series A | 35M |
10/2017 | Cydan | Venture Round | 34M |
3/2022 | Creyon Bio | Series A | 0 |
9/2018 | MouSensor | Seed Round | 3.3M |
1/2019 | Dewpoint Therapeutics | Series A | 60M |
2/2019 | Applied Therapeutics | Series B | 0 |
4/2021 | Molecular Assemblies | Series A | 0 |
9/2018 | OncoResponse | Series B | 40M |
6/2020 | Element Biosciences | Series B | 30M |
1/2021 | AltPep | Series A | 23.1M |
6/2023 | AltPep | Series B | 0 |
10/2022 | Matchpoint Therapeutics | Series A | 70M |
5/2018 | Nohla Therapeutics | Series B | 45M |
11/2017 | Codiak Biosciences | Series C | 76.5M |
12/2020 | Remix Therapeutics | Series A | 65M |
4/2021 | Ventus Therapeutics | Series B | 100M |
11/2019 | Genetron Health | Series D | 71M |
10/2019 | Verseau Therapeutics | Equity | 50M |
1/2017 | Halio | Series C | 65M |
4/2018 | QurAlis | Seed Round | - |
9/2018 | ENB Therapeutics | Series A | 8.1M |
1/2023 | Melonfrost | Seed Round | 7M |
2/2017 | Applied Therapeutics | Series A | 6.1M |
2/2023 | Garuda Therapeutics | Series B | 0 |
5/2021 | Marvin | Seed Round | 0 |
7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
10/2021 | Soli Organic | Venture Round | 0 |
11/2019 | miRecule | Seed Round | 0 |
10/2021 | IpiNovyx Bio | Seed Round | 0 |
5/2021 | miRecule | Venture Round | 0 |
1/2019 | Greenlight Biosciences | Venture Round | 50M |
9/2020 | Sonoma BioTherapeutics | Series A | 0 |
10/2021 | DNA Script | Series C | 0 |
9/2019 | Boundless Bio | Series A | 46.4M |
3/2022 | Affini-T Therapeutics | Venture Round | 0 |
7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
3/2017 | Antiva Biosciences | Series C | 22M |
11/2018 | Ribometrix | Series A | 30M |
9/2018 | Silverback Therapeutics | Series A | 37.5M |
11/2022 | Cajal Neuroscience | Series A | 96M |
1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
4/2020 | Nitrase Therapeutics | Series A | 38M |
5/2021 | TwinStrand Biosciences | Series B | 50M |
12/2021 | Ambys Medicines | Series A | 47M |
6/2018 | Cibus | Series C | 70M |
6/2021 | Senda Biosciences | Series B | 0 |
3/2019 | Prevail Therapeutics | Series B | 50M |
9/2021 | Disc Medicine | Post-IPO Equity | 0 |
9/2021 | Disc Medicine | Series B | 90M |
9/2021 | Asher Bio | Series B | 0 |
3/2019 | Imara | Series B | 0 |
9/2022 | Capstan Therapeutics | Series A | 102M |
4/2019 | Insitro | Series A | 100M |
2/2021 | Ensoma | Series A | 0 |
1/2018 | Expansion Therapeutics | Series A | 55.3M |
9/2021 | ROME Therapeutics | Series B | 0 |
6/2021 | Mnemo Therapeutics | Series A | 90M |
10/2019 | Variant Bio | Series A | 24.7M |
5/2022 | MOMA Therapeutics | Series B | 0 |
9/2021 | Lycia Therapeutics | Series B | 70M |
4/2019 | Arrakis Therapeutics | Series B | 75M |
8/2018 | Magnolia NeuroSciences | Series A | 0 |
6/2021 | Veralox Therapeutics | Series A | 0 |
7/2018 | ORIG3N | Series B | 0 |
5/2023 | Myeloid Therapeutics | Series B | 0 |
5/2021 | Soteria Biotherapeutics | Series A | 42M |
6/2021 | Neurona Therapeutics | Venture Round | 0 |
10/2017 | Ribometrix | Seed Round | 7.5M |
7/2018 | Antiva Biosciences | Series C | 15M |
12/2020 | Vigil Neuroscience | Series A | 50M |
5/2023 | Myeloid Therapeutics | Series A | 0 |
5/2021 | BioTheryX | Series E | 92M |
10/2020 | Dren Bio | Series A | 0 |
5/2021 | Advanced Animal Diagnostics | Series E | 0 |
1/2021 | Blacksmith Medicines | Seed Round | - |
3/2021 | StrideBio | Series B | 0 |
8/2022 | Senda Biosciences | Series C | 123M |
1/2023 | Ensoma | Series B | 0 |
3/2020 | Redpin Therapeutics | Series A | 15.5M |
8/2021 | Sonoma BioTherapeutics | Series B | 0 |
7/2017 | Compass Therapeutics, Inc. | Series A | - |
3/2018 | TCR2 | Series B | 0 |
12/2017 | Metacrine | Series B | 22M |
3/2022 | TRex Bio | Series A | 0 |
2/2018 | Quentis | Series A | 48M |
1/2021 | Dice Therapeutics | Series C | 80M |
5/2022 | Aspen Neuroscience | Series B | 0 |
2/2022 | Kallyope | Series D | 0 |
11/2021 | Acrivon Therapeutics | Series B | 0 |
1/2021 | Senti Biosciences | Series B | 105M |
1/2022 | Korro Bio | Series B | 0 |
6/2023 | Bitterroot Bio | Series A | 0 |
12/2021 | NextVivo | Venture Round | 7.9M |
2/2022 | Ventus Therapeutics | Series C | 0 |
12/2020 | RayzeBio | Series B | 105M |
12/2022 | Dantari | Series A | 0 |
1/2019 | Tiburio Therapeutics | Series A | 31M |
3/2020 | Affinia Therapeutics | Series A | 0 |
9/2018 | Benson Hill | Series C | 65M |
6/2022 | DEM BioPharma | Series A | 0 |
8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
7/2017 | Effector Therapeutics | Series C | 38.6M |
10/2021 | Neumora Therapeutics | Series A | 0 |
3/2022 | Celsius Therapeutics | Series B | 0 |
9/2017 | Gritstone Bio | Series B | 93M |
12/2019 | ImCheck Therapeutics | Series B | 53.2M |
11/2022 | Rezo | Series A | 0 |
2/2022 | Terray Therapeutics | Series A | 0 |
7/2022 | Xilis | Series A | 0 |
6/2021 | RayzeBio | Series C | 108M |
3/2020 | Silverback Therapeutics | Series B | 0 |
4/2021 | Boundless Bio | Series B | 105M |
4/2020 | MOMA Therapeutics | Series A | 86M |
5/2023 | Boundless Bio | Series C | 0 |
9/2018 | System1 Biosciences | Series A | 25M |
6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
6/2019 | BlackThorn Therapeutics | Series B | 76M |
1/2021 | Vera Therapeutics | Series C | 0 |
3/2021 | Insitro | Series C | 400M |
2/2019 | Maze Therapeutics | Series A | 191M |
11/2021 | Antiva Biosciences | Series D | 0 |
3/2023 | Chroma Medicine | Series B | 0 |
11/2018 | NextCure | Series B | 93M |
10/2021 | Mozart Therapeutics | Series A | 0 |
2/2018 | Kallyope | Series B | 66M |
12/2017 | Obsidian Therapeutics | Series A | 0 |
2/2018 | Moderna Therapeutics | Series G | 0 |
10/2021 | Deka Biosciences | Series A | 0 |
7/2020 | Vesigen Therapeutics | Series A | 28.5M |
10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
9/2021 | Acrigen Biosciences | Seed Round | - |
3/2018 | Prevail Therapeutics | Series A | 75M |
6/2022 | Dren Bio | Series B | 0 |
10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
10/2018 | Stoke Therapeutics | Series B | 90M |
1/2022 | Avalo | Convertible Note | 750k |
7/2020 | Vor Biopharma | Series B | 0 |
7/2019 | X-Vax Technology | Series A | 0 |
4/2021 | Alloy Therapeutics | Series C | 75M |
4/2021 | SeQure DX | Series A | 0 |
1/2019 | Frequency Therapeutics | Series B | - |
12/2021 | Meiogenix | Series A | 12.4M |
1/2021 | Myeloid Therapeutics | Series A | 50M |
1/2021 | Encodia | Series C | 75M |
9/2018 | Epic Sciences | Series E | 0 |
9/2022 | Novome | Series B | 0 |
7/2021 | Wugen | Series B | 0 |
7/2022 | Ozette Technologies | Series A | 0 |
7/2022 | Cartography Biosciences | Series A | 0 |
7/2022 | Xilis | Series A | 0 |
6/2022 | DEM BioPharma | Series A | 0 |
6/2022 | Dren Bio | Series B | 0 |
5/2022 | Pleno | Seed Round | 0 |
5/2022 | Remix Therapeutics | Series B | 0 |
5/2022 | MOMA Therapeutics | Series B | 0 |
5/2022 | Aspen Neuroscience | Series B | 0 |
4/2022 | Pheast Therapeutics | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|